Cargando…
Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes
Induced pluripotent stem cells (iPSCs) have the ability to differentiate into cardiomyocytes (CMs). They are not only widely used in cardiac pharmacology screening, human heart disease modeling, and cell transplantation-based treatments, but also the most promising source of CMs for experimental and...
Autores principales: | Wu, Peng, Deng, Gang, Sai, Xiyalatu, Guo, Huiming, Huang, Huanlei, Zhu, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209171/ https://www.ncbi.nlm.nih.gov/pubmed/33057659 http://dx.doi.org/10.1042/BSR20200833 |
Ejemplares similares
-
MiR-21 attenuates FAS-mediated cardiomyocyte apoptosis by regulating HIPK3 expression
por: Wang, Xinyu, et al.
Publicado: (2023) -
Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo
por: Clerk, Angela, et al.
Publicado: (2022) -
Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice
por: Alharbi, Hajed O., et al.
Publicado: (2022) -
Maturation of induced pluripotent stem cell-derived cardiomyocytes and its therapeutic effect on myocardial infarction in mouse
por: Wu, Peng, et al.
Publicado: (2022) -
MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins
por: Fuller, Stephen J., et al.
Publicado: (2021)